Bexsero (meningococcal group B vaccine) / GSK  >>  Phase 3
Welcome,         Profile    Billing    Logout  

14 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bexsero (meningococcal group B vaccine) / GSK
2017-004520-30: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers when Administered Concomitantly with Routine Pediatric Vaccines in the UK.

Not yet recruiting
3
700
Europe
MenACYW Conjugate Vaccine, Bexsero, 395, Solution for injection, Suspension for injection in pre-filled syringe, BEXSERO (Meningococcal group B Vaccine (rDNA, component, adsorbed))
Sanofi Pasteur, Sanofi Pasteur
Active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W)., Invasive meningogoccal disease (IMD), Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2019-000924-17: Multicenter, randomized, phase III, trial assessing the immunogenicity and safety of three meningococal B vaccine strategies among patients with asplenia Essai multicentrique, randomisé de phase III, évaluant l'immunogénicité et la tolérance de trois stratégies vaccinales contre le méningocoque B chez des patients présentant une asplénie

Not yet recruiting
3
84
Europe
Solution for injection, Bexsero®, Trumenba®
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, DGOS
asplenic patients at risk for invasive meningococcal disease Patients splénectomisés à risque d'infection à meningocoque B, asplenic patients patients splénectomisés, Body processes [G] - Immune system processes [G12]
 
 
2020-004385-19: Long-term safety and tolerability of iptacopan in patients with Paroxysmal Nocturnal Hemoglobinuria

Ongoing
3
165
Europe
iptacopan, LNP023, Capsule, hard, PNEUMOVAX – Soluzione iniettabile in siringa preriempita da 0,5 ml, ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML, MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC, BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO, Nimenrix, HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML
Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Farmacéutica, S.A., Novartis Pharma AG
Paroxysmal Nocturnal Hemoglobinuria (PNH), Blood disorder, Diseases [C] - Immune System Diseases [C20]
 
 
MET52, NCT03632720: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom

Completed
3
788
Europe
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine, MenACYW Conjugate vaccine, Meningococcal group B vaccine, Bexsero®, Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine, Infanrix hexa®, Human rotavirus RIX4414 strain vaccine, Rotarix®, Pneumococcal 13-valent polysaccharide conjugate vaccine, Prevenar 13®
Sanofi Pasteur, a Sanofi Company
Healthy Volunteers (Meningococcal Infection)
12/22
12/22
DOXYVAC, NCT04597424: Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP)

Active, not recruiting
3
556
Europe
Experimental: doxycycline, Bexsero® vaccine
ANRS, Emerging Infectious Diseases
Unsafe Sex, Risk-Taking
02/23
09/23
MenABCWY – 019, NCT04707391 / 2019-004982-42: Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Completed
3
1250
Canada, US, RoW
MenABCWY vaccine, Placebo, MenACWY vaccine, Menveo, MenB vaccine, Bexsero
GlaxoSmithKline
Meningitis, Meningococcal
05/23
09/23
2022-000460-21: Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. Seguridad y eficacia de ALXN1720 en adultos con miastenia gravis generalizada.

Not yet recruiting
3
200
Europe
Bexsero, na, Menveo, Ciprofloxacino normon 500mg, Eritromicina normon 500mg, Ciprofloxacina, Penilevel 500mg, ALXN1720, Concentrate for solution for injection, BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO, MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC, Menveo, Ciprofloxacino cinfa 500mg- cn 6970157, Ciprofloxacino normon 500mg -cn 6956212, Eritromicina normon 500mg – cn 6940167, Amoxicillina Almus 500, Bexsero, Ciprofloxacino teva 500mg – cn 6944967, Penilevel 500mg- cn 7135050
Alexion Pharmaceuticals, Inc, ALEXION PHARMACEUTICALS INCORPORATED, Alexion Pharmaceuticals, Inc, Alexion Pharmaceuticals, Inc.
Generalized Myasthenia Gravis Miastenia Gravis Generalizada, Generalized Myasthenia Gravis Miastenia Gravis Generalizada, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04318548 / 2016-003722-16: Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

Active, not recruiting
3
943
Europe, US
Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Bexsero, Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid), Menveo, Placebo, NaCl, saline solution
GlaxoSmithKline
Infections, Meningococcal
11/23
07/24
NCT06446752: BIYELA - Bexsero Immunisation in Young Women in Africa

Not yet recruiting
3
1100
RoW
Bexsero, 4MenB-4C, Placebo, Saline
University of Washington, Bill and Melinda Gates Foundation, University of Witwatersrand, South Africa
Gonorrhea, Gonorrhea of Pharynx, Gonorrhea of Anus, Gonorrhea of Cervix
05/26
08/26
NCT03621670 / 2016-003268-37: Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Active, not recruiting
3
1200
US
Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, Placebo (saline water), Prevnar 20
GlaxoSmithKline
Infections, Meningococcal
10/24
10/24
GoGoVax, NCT04415424: Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men

Active, not recruiting
3
652
RoW
4CMenB vaccine, Bexsero®, Placebo
Kirby Institute, Griffith University
Neisseria Gonorrheae Infection
10/24
02/25
NCT05766904: Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections

Recruiting
3
150
RoW
4CMenB vaccine, Bexsero, Placebo
Chinese University of Hong Kong
Gonorrhea, Sexually Transmitted Infection
03/25
09/25
SPLEMENGO, NCT04166656: Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.

Recruiting
3
84
Europe
Trumenba®, Bexsero®
Assistance Publique - Hôpitaux de Paris, EUCLID Clinical Trial Platform, Recherche Clinique Paris Descartes Necker Cochin Sainte Anne, CIC 1417 Cochin-Pasteur, Innovative clinical research in vaccinologie (I-REIVAC), Institut Pasteur
Splenectomy
09/28
10/28
ACTRN12623000738628: VIRGo – Vaccine-induced Immune Responses against Gonorrhoea: A study to investigate immune response induced by the 4CMenB vaccine against gonorrhoea

Not yet recruiting
2/3
60
 
Gold Coast University Hospital, National Health and Medical Research Council
gonorrhoea
 
 

Download Options